Trade

with

Exelixis Inc
(NASDAQ: EXEL)
AdChoices
1.59
-0.01
-0.63%
After Hours :
1.59
0.00
0.00%

Open

1.59

Previous Close

1.60

Volume (Avg)

1.28M (4.43M)

Day's Range

1.57-1.62

52Wk Range

1.35-8.41

Market Cap.

312.18M

Dividend Rate ( Yield )

-

Beta

2.47

Shares Outstanding

195.11M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 31.34M

    • Net Income

    • -244.76M

    • Market Cap.

    • 312.18M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,343.51

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.47

    • Forward P/E

    • -3.33

    • Price/Sales

    • 14.20

    • Price/Book Value

    • 96.15

    • Price/Cash flow

    • -1.28

      • EBITDA

      • -196.36M

      • Return on Capital %

      • -54.32

      • Return on Equity %

      • -286.51

      • Return on Assets %

      • -54.32

      • Book Value/Share

      • 0.02

      • Shares Outstanding

      • 195.11M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 11.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.48

        • Cashflow Estimate

        • -0.43

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -44.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -23.27

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 93.71

            • 82.75

            • Pre-Tax Margin

            • -1,343.96

            • 39.38

            • Net Profit Margin

            • -1,343.51

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 99.30

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -241.70

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -241.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 78.23

              • 0.76

              • Current Ratio

              • 1.50

              • 2.92

              • Quick Ratio

              • 1.39

              • 2.35

              • Interest Coverage

              • -5.10

              • 38.02

              • Leverage Ratio

              • 135.87

              • 2.21

              • Book Value/Share

              • 0.02

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.04

                • 196.08

                • P/E Ratio 5-Year High

                • -8.47

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.89

                • 124.82

                • Price/Sales Ratio

                • 13.97

                • 9.12

                • Price/Book Value

                • 94.34

                • 8.26

                • Price/Cash Flow Ratio

                • -1.28

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -286.51

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -54.32

                    (-21.80)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -54.03

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 0.72

                  • 1.48

                  • Asset Turnover

                  • 0.04

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -200.73M
                  Operating Margin
                  -640.54
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.28
                  Ownership

                  Institutional Ownership

                  69.47%

                  Top 10 Institutions

                  54.45%

                  Mutual Fund Ownership

                  46.78%

                  Float

                  49.44%

                  5% / Insider Ownership

                  1.61%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    14,157,387

                  • 0.26

                  • 7.26

                  • SPDR® S&P Biotech ETF

                  •  

                    9,468,576

                  • 3.60

                  • 5.23

                  • T. Rowe Price Health Sciences Fund

                  •  

                    6,263,000

                  • -0.31

                  • 3.21

                  • T. Rowe Price New Horizons Fund

                  •  

                    6,235,500

                  • -2.11

                  • 3.20

                  • Fidelity® Series Growth Company Fund

                  •  

                    3,405,304

                  • 0.26

                  • 1.75

                  • Vanguard Small Cap Index

                  •  

                    3,067,481

                  • 0.46

                  • 1.57

                  • iShares Russell 2000 (AU)

                  •  

                    3,033,349

                  • -1.02

                  • 1.68

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,864,801

                  • 0.00

                  • 1.47

                  • Fidelity® Blue Chip Growth Fund

                  •  

                    2,632,000

                  • 0.00

                  • 1.35

                  • iShares Nasdaq Biotechnology

                  •  

                    2,590,002

                  • -0.69

                  • 1.43

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • T. Rowe Price Associates, Inc.

                  •  

                    19,295,340

                  • -0.32%

                  • 9.89

                  • Meditor Capital Management Limited

                  •  

                    19,070,213

                  • +6.70%

                  • 9.78

                  • Fidelity Management and Research Company

                  •  

                    17,135,441

                  • +4.82%

                  • 8.78

                  • Wellington Management Company, LLP

                  •  

                    16,240,816

                  • -21.74%

                  • 8.32

                  • Vanguard Group, Inc.

                  •  

                    10,946,386

                  • -0.70%

                  • 5.61

                  • State Street Corp

                  •  

                    7,217,244

                  • +18.88%

                  • 3.70

                  • BlackRock Fund Advisors

                  •  

                    6,606,408

                  • -8.83%

                  • 3.39

                  • Government Pension Fund of Norway - Global

                  •  

                    3,207,690

                  • +275.77%

                  • 2.37

                  • Goldman, Sachs & Co.

                  •  

                    2,842,003

                  • -10.06%

                  • 1.46

                  • Northern Trust Investments, N.A.

                  •  

                    2,248,478

                  • -13.04%

                  • 1.15

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  Exelixis Inc incorporated in November, 1994. It is a biotechnology company which develops small molecule therapies to treat cancer. Its two advanced assets, COMETRIQ® "cabozantinib", its wholly-owned inhibitor of multiple receptor ty...morerosine kinases, and cobimetinib "GDC-0973/XL518", a potent, highly selective inhibitor of MEK, which it out-licensed to Genentech, Inc. a wholly-owned member of the Roche Group, or Genentech, are currently the subject of six ongoing phase 3 pivotal trials. Cabozantinib is being evaluated in a development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer or CRPC, an ongoing phase 3 pivotal trial in metastatic renal cell cancer or RCC, and an ongoing phase 3 pivotal trial in advanced hepatocellular cancer, or HCC. The ...moreprograms that the Company runs are Cabozantinib Development Program, CRPC, COMET Pivotal Trials, Combination trials. The Company has development programs in collaboration with Genentech, GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited. It contracts third parties to manufacture raw materials, the active pharmaceutical ingredient, or API, and finished solid dose COMETRIQ products for clinical and commercial uses. The Company follows regulations set forth by FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries. Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, are applicable to the Company.lessless

                  Key People

                  Dr. Michael M. Morrissey, PhD

                  CEO/Director/President

                  Dr. Stelios Papadopoulos,PhD

                  Chairman of the Board/Co-Founder/Director

                  Ms. Deborah Burke

                  CFO/Chief Accounting Officer/Controller/Senior VP

                  Dr. Gisela M. Schwab,M.D.

                  Chief Medical Officer/Executive VP

                  Dr. Peter Lamb,PhD

                  Chief Scientific Officer/Executive VP, Divisional

                  • Exelixis Inc

                  • 210 East Grand Avenue

                  • South San Francisco, CA 94080

                  • USA.Map

                  • Phone: +1 650 837-7000

                  • Fax: +1 650 837-8300

                  • exelixis.com

                  Incorporated

                  1994

                  Employees

                  227

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: